Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec 8;2(61):61rv6.
doi: 10.1126/scitranslmed.3000446.

Lost in translation: neuropsychiatric drug development

Robert E Becker  1 , Nigel H Greig
Affiliations
Review

Lost in translation: neuropsychiatric drug development

Robert E Becker et al. Sci Transl Med. .

Abstract

Recent studies have identified troubling method and practice lapses in neuropsychiatric drug developments. These problems have resulted in errors that are of sufficient magnitude to invalidate clinical trial data and interpretations. We identify two potential sources for these difficulties: investigators selectively choosing scientific practices for demonstrations of efficacy in human-testing phases of drug development and investigators failing to anticipate the needs of practitioners who must optimize treatment for the individual patient. When clinical investigators neglect to use clinical trials as opportunities to test hypotheses of disease mechanisms in humans, the neuropsychiatric knowledge base loses both credibility and scope. When clinical investigators do not anticipate the need to translate discoveries into applications, the practitioner cannot provide optimal care for the patient. We conclude from this evidence that clinical trials, and other aspects of neuropsychiatric drug development, must adopt more practices from basic science and show greater responsiveness to conditions of clinical practice. We feel that these changes are necessary to overcome current threats to the validity and utility of studies of neurological and psychiatric drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Problems in neuropsychiatric drug discovery.
Figure 2
Figure 2
Inadequate options for neuropsychiatric patients.
Figure 3
Figure 3
The way forward.
Figure 4
Figure 4
The black hole of neuropsychiatry drug development.
See this image and copyright information in PMC

References

    1. Sackett DL, Strauss SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. New York: Churchill Livingstone; 2000.
    1. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology. 2009;34:74–89. - PMC - PubMed
    1. Engelhardt N, Feiger AD, Cogger KO, Sikich D, DeBrota DJ, Lipsitz JD, Kobak KA, Evans KR, Potter WZ. Rating the raters: Assessing the quality of Hamilton Rating Scale for Depression clinical interviews in two industry-sponsored clinical drug trials. J. Clin. Psychopharmacol. 2006;26:71–74. - PubMed
    1. Cogger KO. Rating rater improvement: A method for estimating increased effect size and reduction of clinical trial costs. J. Clin. Psychopharmacol. 2007;27:418–420. - PubMed
    1. Becker RE, Markwell S. Problems arising from generalizing of treatment efficacy from clinical trials in Alzheimer’s disease. Clin. Drug Invest. 2000;19:33–41.

Publication types